Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice

Maternal antibodies provide short-term protection to infants against many infections. However, they can inhibit de novo antibody responses in infants elicited by infections or vaccination, leading to increased long-term susceptibility to infectious diseases. Thus, there is a need to develop vaccines...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Science translational medicine Ročník 12; číslo 525
Hlavní autoři: Willis, Elinor, Pardi, Norbert, Parkhouse, Kaela, Mui, Barbara L, Tam, Ying K, Weissman, Drew, Hensley, Scott E
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 08.01.2020
Témata:
Adjuvants, Immunologic - pharmacology
Animals
Antibodies, Viral - immunology
Antibody Formation - immunology
Disease Models, Animal
Female
Germinal Center
Hemagglutinin Glycoproteins, Influenza Virus - immunology
Influenza Vaccines - immunology
Lipids - chemistry
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Nanoparticles - chemistry
Nucleosides - metabolism
Orthomyxoviridae - immunology
Orthomyxoviridae Infections - immunology
Orthomyxoviridae Infections - prevention & control
Orthomyxoviridae Infections - virology
RNA, Messenger - immunology
Vaccination
ISSN:1946-6242, 1946-6242
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Maternal antibodies provide short-term protection to infants against many infections. However, they can inhibit de novo antibody responses in infants elicited by infections or vaccination, leading to increased long-term susceptibility to infectious diseases. Thus, there is a need to develop vaccines that are able to elicit protective immune responses in the presence of antigen-specific maternal antibodies. Here, we used a mouse model to demonstrate that influenza virus-specific maternal antibodies inhibited de novo antibody responses in mouse pups elicited by influenza virus infection or administration of conventional influenza vaccines. We found that a recently developed influenza vaccine, nucleoside-modified mRNA encapsulated in lipid nanoparticles (mRNA-LNP), partially overcame this inhibition by maternal antibodies. The mRNA-LNP influenza vaccine established long-lived germinal centers in the mouse pups and elicited stronger antibody responses than did a conventional influenza vaccine approved for use in humans. Vaccination with mRNA-LNP vaccines may offer a promising strategy for generating robust immune responses in infants in the presence of maternal antibodies.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1946-6242
1946-6242
DOI:10.1126/scitranslmed.aav5701